Skip to content
Abierto

Sources sought

Cryopreserved Platelets (CPP) for US FDA Licensure

HT9427-26-RFI-705

Defense Health Agency (Dha), Army Med Res Acq Activity. Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).

Response deadline

May 4, 2026 at 3:00 PM EDT

Closed 136 days ago. Posted April 28, 2026, first published April 23, 2026. Scheduled to archive May 19, 2026.

Description

As published on SAM.gov.

Defense Health Agency seeks to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation. We develop, directly through collaboration with commercial partners, medical products that enhance readiness and improve the quality of life of active-duty personnel in the operational environment. OPMED’s WPAC PMO has been developing a biologic product: Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP), a frozen, biologic-platelet product.

DMSO CPP are formulated to provide a platelet-derived product with a longer shelf life (2 years and potentially longer) than liquid stored platelets (LSP), which are currently licensed for storage up to 5-7 days at room temperature (20ºC to 24ºC) under gentle agitation.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. April 23, 2026

    Sources sought

    Due May 4, 2026 at 3:00 PM EDT. SAM.gov, notice 6af44860d1524f628c0124e06e4bb8b6

  2. April 28, 2026

    Sources sought

    Due May 4, 2026 at 3:00 PM EDT. SAM.gov, notice e2c26dc3937049faa715f6fa7fad2308

Points of contact